Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 7, 2014, Pages

  Wang, Jing ^a   Badeanlou, Leylla ^a   Bielawski, Jacek ^b   Ciaraldi, Theodore P ^c,d   Samad, Fahumiya ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adipogenesis; Adipose inflammation; Insulin resistance; Sphingosine 1 phosphate; Sphingosine kinase 1

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; INSULIN; INTERLEUKIN 6; METFORMIN; ROSIGLITAZONE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ADIPOSE TISSUE MACROPHAGE; ADULT; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MACROPHAGE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ADIPOGENESIS; ADIPOSE INFLAMMATION; INSULIN RESISTANCE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; AGED; ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; OBESITY; PANNICULITIS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 84900558183     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00549.2013     Document Type: Article

References (49)

1. Armani A, Mammi C, Marzolla V, Calanchini M, Antelmi A, Rosano GM, Fabbri A, Caprio M. Cellular models for understanding adipogenesis, adipose dysfunction, and obesity. J Cell Biochem 110: 564-572, 2010.
2. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F. Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med 17: 1490-1497, 2011.
3. Baker DA, Barth J, Chang R, Obeid LM, Gilkeson GS. Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis. J Immunol 185: 2570-2579, 2010.
4. Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, Remaley AT, Saba JD, Proia RL. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 285: 10880-10889, 2010.
5. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91, 2006.
6. Blachnio-Zabielska AU, Koutsari C, Tchkonia T, Jensen MD. Sphingolipid content of human adipose tissue: relationship to adiponectin and insulin resistance. Obesity (Silver Spring) 20: 2341-2347, 2012.
7. Boon J, Hoy AJ, Stark R, Brown RD, Meex RC, Henstridge DC, Schenk S, Meikle PJ, Horowitz JF, Kingwell BA, Bruce CR, Watt MJ. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 62: 401-410, 2013.
8. Bruce CR, Risis S, Babb JR, Yang C, Kowalski GM, Selathurai A, Lee-Young RS, Weir JM, Yoshioka K, Takuwa Y, Meikle PJ, Pitson SM, Febbraio MA. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in highfat diet-fed mice. Diabetes 61: 3148-3155, 2012.
9. Bruce CR, Risis S, Babb JR, Yang C, Lee-Young RS, Henstridge DC, Febbraio MA. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice. Endocrinology 154: 65-76, 2013.
10. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46: 2347-2355, 2005.
11. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 4: 263-273, 2006.
12. Gorska M, Dobrzyn A, Baranowski M. Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes. Med Sci Monit 11: CR35-CR38, 2005.
13. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S, Spiegel S. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J 22: 2629-2638, 2008.
14. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367-377, 2008.
15. Hashimoto T, Igarashi J, Kosaka H. Sphingosine kinase is induced in mouse 3T3-L1 cells and promotes adipogenesis. J Lipid Res 50: 602-610, 2009.
16. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, DeFronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337-343, 2009.
17. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5: 167-179, 2007.
18. Jun DJ, Lee JH, Choi BH, Koh TK, Ha DC, Jeong MW, Kim KT. Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology 147: 5835-5844, 2006.
19. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846, 2006.
20. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE. Obesityassociated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117: 2621-2637, 2007.
21. Kolak M, Gertow J, Westerbacka J, Summers SA, Liska J, Franco-Cereceda A, Orešic M, Yki-Järvinen H, Eriksson P, Fisher RM. Expression of ceramide-metabolising enzymes in subcutaneous and intraabdominal human adipose tissue. Lipids Health Dis 11: 115, 2012.
22. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH Jr, Futerman AH. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283: 5677-5684, 2008.
23. Li P, Fan W, Xu J, Lu M, Yamamoto H, Auwerx J, Sears DD, Talukdar S, Oh D, Chen A, Bandyopadhyay G, Scadeng M, Ofrecio JM, Nalbandian S, Olefsky JM. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 147: 815-826, 2011.
24. Ma MM, Chen JL, Wang GG, Wang H, Lu Y, Li JF, Yi J, Yuan YJ, Zhang QW, Mi J, Wang LS, Duan HF, Wu CT. Sphingosine kinase 1 participates in insulin signaling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 50: 891-900, 2007.
25. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22: 50-60, 2012.
26. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH Jr, Milstien S, Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280: 37118-37129, 2005.
27. Moon MH, Jeong JK, Lee JH, Park YG, Lee YJ, Seol JW, Park SY. Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model. Exp Mol Med 44: 603-614, 2012.
28. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246, 2010.
29. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18: 363-374, 2012.
30. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112: 1382-1391, 2008.
31. Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, Sumbayev VV. The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol 89: 268-274, 2011.
32. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52: 667-674, 2003.
33. Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE, Conrad D, Ryan JJ, Milstien S, Spiegel S. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol 131: 501-511, 2013.
34. Puneet P, Yap CT, Wong L, Lam Y, Koh DR, Moochhala S, Pfeilschifter J, Huwiler A, Melendez AJ. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328: 1290-1294, 2010.
35. Samad F, Badeanlou L, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol 721: 67-86, 2011.
36. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55: 2579-2587, 2006.
37. Samad FB, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. In: Sphingolipids and Metabolic Disease, edited by Cowart A. New York: Springer Science and Business Media, Landes Bioscience, 2010.
38. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283: 13538-13548, 2008.
39. Shi H, Cave B, Inouye K, Bjørbaek C, Flier JS. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55: 699-707, 2006.
40. Shi H, Tzameli I, Bjørbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279: 34733-34740, 2004.
41. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11: 403-415, 2011.
42. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131, 2006.
43. Turner N, Kowalski GM, Leslie SJ, Risis S, Yang C, Lee-Young RS, Babb JR, Meikle PJ, Lancaster GI, Henstridge DC, White PJ, Kraegen EW, Marette A, Cooney GJ, Febbraio MA, Bruce CR. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 56: 1638-1648, 2013.
44. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 21: 345-352, 2010.
45. van Tienen FH, van der Kallen CJ, Lindsey PJ, Wanders RJ, van Greevenbroek MM, Smeets HJ. Preadipocytes of type 2 diabetes subjects display an intrinsic gene expression profile of decreased differentiation capacity. Int J Obes (Lond) 35: 1154-1164, 2011.
46. van Beekum O, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17: 213-219, 2009.
47. Wang MY, Grayburn P, Chen S, Ravazzola M, Orci L, Unger RH. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci USA 105: 6139-6144, 2008.
48. Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saltiel AR, Lumeng CN. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 206: 3143-3156, 2009.
49. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 297: E211-E224, 2009.